Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view.
Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view.
复制标题
炎症、动脉粥样硬化和心血管风险：流行病学观点。
DOI：
--
复制
发表时间：
1999
影响因子：
1.1
通讯作者：
P. Ridker
中科院分区：
文献类型：
--
作者：
P. Ridker
根据实验室和实验证据，已经假设炎症在动脉粥样硬化形成和急性血栓形成中起基础作用。从流行病学的角度来看，一系列前瞻性队列研究证实了这一假设，这些研究表明，在有未来冠状动脉闭塞风险的患者中，炎症参数(如纤维蛋白原、C反应蛋白和血清淀粉样蛋白A)、细胞黏附分子[如细胞间黏附分子(ICAM)-1]和细胞因子(如白介素6)均在基线水平升高。此外，来自随机临床试验的数据表明，阿司匹林和羟甲基戊二醛(HMG)辅酶A还原酶抑制等常见预防药物的疗效可能部分源于与炎症系统的相互作用。综上所述，这些数据增加了针对慢性低度炎症的治疗可能为心血管疾病预防提供新的未来策略的可能性。
Based on laboratory and experimental evidence, it has been hypothesized that inflammation plays a fundamental role in atherogenesis and acute thrombosis. From an epidemiologic perspective, corroboration of this hypothesis has been provided by a series of prospective cohort studies which demonstrate that inflammatory parameters (such as fibrinogen, C reactive protein, and serum amyloid A), cellular adhesion molecules [such as intercellular adhesion molecule (ICAM)-1], and cytokines (such as interleukin-6) are all elevated at baseline among patients at risk for future coronary occlusion. Furthermore, data deriving from randomized clinical trials suggest that the efficacy of common preventive agents such as aspirin and hydroxy-methylglutaryl (HMG) CoA reductase inhibition may derive in part from interactions with the inflammatory system. Taken together, these data raise the possibility that therapies targeting chronic low-grade inflammation may provide novel future strategies for cardiovascular disease prevention.